



Bl

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/535		A1	(11) International Publication Number: WO 99/64009
			(43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/GB99/01818 (22) International Filing Date: 8 June 1999 (08.06.99) (30) Priority Data: 9812662.6 11 June 1998 (11.06.98) GB (71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): RUPNIAK, Nadia, Mélanie [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: HISCOCK, Ian, James; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: USE OF AN NK-1 RECEPTOR ANTAGONIST FOR TREATING COGNITIVE DISORDERS			
(57) Abstract The present invention provides the use of an NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders, methods of medical treatment using such an NK-1 receptor antagonist and pharmaceutical compositions comprising it.			
BEST AVAILABLE COPY			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF A NK-1 RECEPTOR ANTAGONIST
FOR TREATING COGNITIVE DISORDERS

This invention relates to the treatment or prevention of certain
5 cognitive disorders by the administration of a NK-1 receptor antagonist, in particular, 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

Cognitive disorders include dementia, amnestic disorders and
10 cognitive disorders not otherwise specified. The prominent disturbance associated with these conditions is a clinically significant deficit in cognition or memory that represents a significant change from a previous level of functioning.

For instance, dementia is now defined as a syndrome consisting of
15 progressive impairment in two or more areas of cognition (i.e. memory, language, visuospatial and perceptual ability, thinking and problem solving, and personality) sufficient to interfere with work, social function or relationships.

An amnestic disorder is characterised by memory impairment in the
20 absence of other significant cognitive impairments.

Pharmacological treatment of such cognitive disorders is poorly
developed. In some instances, antidepressants, hypnotics or
antipsychotics may be used in order to manage specific behavioural
disturbances associated with the cognitive disorder. Such treatments,
25 however, may be compromised by the side effects associated with these classes of pharmacological agent and, as such, are far from ideal means for treating cognitive disorders.

Neurokinin 1 (NK-1; substance P) receptor antagonists are being
developed for the treatment of a number of physiological disorders
30 associated with an excess or imbalance of tachykinins, and in particular substance P. Examples of conditions in which substance P has been

implicated include disorders of the central nervous system such as anxiety, depression and psychosis (see, for instance, International (PCT) patent specification Nos. WO 95/16679, WO 95/18124 and WO 95/23798).

More recently, International (PCT) patent specification No. WO
5 96/24353 (published 15th August 1996) suggests that a more efficacious and safe treatment of psychiatric disorders would be achieved using a combination of a tachykinin antagonist and a serotonin agonist or selective serotonin reuptake inhibitor (SSRI). However, such a regimen would not be free of side-effects due to the serotonin agonist or SSRI.

10 In view of the short-comings of existing therapy, there is a need for new, safe and effective treatment for cognitive disorders.

The present invention provides the use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt
15 thereof in an oral, once-a-day medicament for the treatment of cognitive disorders. The compounds of this class advantageously exhibit a rapid onset of action and a reduced side-effect profile when compared against conventional antidepressant or antipsychotic agents.

The exceptional pharmacology of the NK-1 receptor antagonist of
20 use in the present invention enables the treatment of cognitive disorders, without the need for concomitant therapy using tricyclic antidepressants or monoamine oxidase inhibitors, or antipsychotic agents, or in particular, without the need for concomitant use of a serotonin agonist or an SSRI.

Furthermore, the exceptional pharmacology of the NK-1 receptor
25 antagonist of use in the present invention results in a rapid onset of action.

The present invention accordingly provides the use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable
30 salt thereof, for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders.

The present invention also provides a method for the treatment or prevention of cognitive disorders, which method comprises the oral administration to a patient in need of such treatment of an effective amount of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-
5 3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

In a further aspect of the present invention, there is provided an oral pharmaceutical composition for the treatment of cognitive disorders which comprises 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-
10 hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.

There exists a patient population in whom cognitive disorders are inadequately treated with existing antidepressant therapy. Furthermore,
15 some patients may be adversely affected by the side-effects of existing antidepressant drugs.

The present invention accordingly provides the use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-
4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable
20 salt thereof, for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine
25 reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated.

The present invention also provides a method for the treatment or
30 prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs,

serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and
5 norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a
10 pharmaceutically acceptable salt thereof.

Furthermore, there exists a patient population in whom cognitive disorders are inadequately treated with existing antipsychotic therapy. Furthermore, some patients may be adversely affected by the side-effects of antipsychotic drugs.

15 The present invention accordingly provides the use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a
20 patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated.

The present invention also provides a method for the treatment or prevention of cognitive disorders in the patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are
25 contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

30 As used herein, the term "cognitive disorders" includes dementia, amnesic disorders and cognitive disorders not otherwise specified.

In particular, the term "cognitive disorders" includes dementia caused by degenerative disorders, lesions, trauma, infections, vascular disorders, toxins, anoxia, vitamin deficiency and endocrine disorders. Specific examples of these causes include degenerative disorders such as

5 Alzheimer's disease, multiple sclerosis, Parkinson's disease, normal pressure hydrocephalus and Huntington's chorea; space occupying lesions including tumors and chronic subdural haematoma; trauma including severe head injury; infections including postencephalitis and syphilis; vascular disorders including multi-infarct dementia; toxins including

10 alcohol; anoxia caused by cardiac arrest and carbon monoxide poisoning, vitamin deficiencies including lack of vitamin B₁₂; and endocrine disorders including hypothyroidism.

Furthermore, the term "cognitive disorders" includes amnesic disorders caused by alcohol (Korsakoff psychosis) and other causes of

15 thiamine deficiency; bilateral temporal lobe damage due to herpes simplex encephalitis and other limbic encephalitis, neuronal loss secondary to anoxia/hypoglycaemia/severe convulsions, and surgery; degenerative disorders including Alzheimer's and Pick's diseases; vascular disorders including bilateral infarction, hippocampal infarction and bilateral

20 cingulate cortex infarction; and pathology around ventricle III including tumors, chronic meningitis and neurosarcoidosis.

Also, as used herein, the term "cognitive disorders" includes cognitive impairment resulting from other medical conditions, most especially resulting from depression and/or anxiety.

25 As used herein, the term "treatment" refers both to the treatment and to the prevention or prophylactic therapy of the aforementioned conditions.

In particular, the NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-

30 hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

Full descriptions of the preparation of the NK-1 receptor antagonist which may be employed in the present invention may be found in International Patent Specification No. WO 95/18124 and US Patent No. 5,612,337.

5 Suitable pharmaceutically acceptable salts of the NK-1 receptor antagonist of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as
10 citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.

Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group.

Preferably the compositions containing the NK-1 receptor
15 antagonist of use according to the present invention are in unit dosage forms such as tablets, pills, capsules, wafers and the like. Additionally, the NK-1 receptor antagonist of use according to the present invention may be presented as granules or powders for extemporaneous formulation as volume defined solutions or suspensions. Alternatively, the NK-1
20 receptor antagonist of use according to the present invention may be presented in ready-prepared volume defined solutions or suspensions. Preferred forms are tablets and capsules.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional
25 tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
30 When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the

composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.

10 The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

15

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

20

25 Compositions of the present invention may also be administered via the buccal cavity using conventional technology, for example, absorption wafers.

Compositions in the form of tablets, pills, capsules or wafers for oral administration are particularly preferred.

30 A minimum dosage level for the NK-1 receptor antagonist is about 1mg per day, preferably about 5mg per day and especially about 10mg per

day. A maximum dosage level for the NK-1 receptor antagonist is about 1500mg per day, preferably about 1000mg per day and especially about 500mg per day. The compounds are administered once a day.

It will be appreciated that the amount of the NK-1 receptor antagonist required for use in the treatment or prevention of cognitive disorders will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.

The activity of the NK-1 receptor antagonist of use in the present invention may be measured using the following assays:

ASSAY 1: NK-1 Receptor binding

NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri *et al*, *J. Pharmacol. Exp. Ther.*, 1992, 42, 458. Typically the receptor is expressed at a level of 3×10^5 receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay. ^{125}I -Tyr⁸-substance P (0.1nM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 5 μ l dimethylsulphoxide, DMSO) with 5×10^4 CHO cells. Ligand binding is performed in 0.25ml of 50mM Tris-HCl, pH7.5, containing 5mM MnCl_2 , 150mM NaCl, 0.02% bovine serum albumin (Sigma), 50 μ g/ml chymostatin (Peninsula), 0.1nM phenylmethylsulphonyl fluoride, 2 μ g/ml pepstatin, 2 μ g/ml leupeptin and 2.8 μ g/ml furoyl saccharine. The incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters pre-soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Non-

specific binding is determined using excess substance P (1 μ M) and represents <10% of total binding.

ASSAY 2: Gerbil Foot-Tapping

5 CNS-penetrant NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by anxiogenic agents (such as pentagastrin) or central infusion of NK-1 receptor agonists such as GR73632, or caused by aversive stimulation such as foot shock or single housing, based on the method of
10 Rupniak & Williams, *Eur. J. Pharmacol.*, 1994, 265, 179.

----- Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of 5ml/kg i.v. Alternatively, test compounds may be
15 administered orally or by subcutaneous or intraperitoneal routes. A skin incision is then made in the midline of the scalp to expose the skull. An anxiogenic agent (e.g. pentagastrin) or a selective NK-1 receptor agonist (e.g. GR73632 (d Ala[L-Pro⁹,Me-Leu¹⁰]-substance P-(7-11)) is infused directly into the cerebral ventricles (e.g. 3pmol in 5 μ l i.c.v., depending on
20 test substance) by vertical insertion of a cuffed 27 gauge needle to a depth of 4.5mm below bregma. The scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (25cm x 20cm x 20cm). The duration and/or intensity of hind foot tapping is then recorded continuously for approximately 5 minutes. Alternatively,
25 the ability of test compounds to inhibit foot tapping evoked by aversive stimulation, such as foot shock or single housing, may be studied using a similar method of quantification.

ASSAY 3: Ferret Emesis

30 Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with

approximately 100g of tinned cat food. At 60 minutes following oral dosing, cisplatin (10mg/kg) is given i.v. *via* a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The
5 ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the anaesthetic and for 4 hours following the cisplatin injection, after which time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administration are recorded
10 by trained observers.

ASSAY 4: Separation-Induced Vocalisation

Male and female guinea-pigs pups are housed in family groups with their mothers and littermates throughout the study. Experiments are
15 commenced after weaning when the pups are 2 weeks old. Before entering an experiment, the pups are screened to ensure that a vigorous vocalisation response is reproducibly elicited following maternal separation. The pups are placed individually in an observation cage (55cm x 39cm x 19cm) in a room physically isolated from the home cage for
20 15 minutes and the duration of vocalisation during this baseline period is recorded. Only animals which vocalise for longer than 5 minutes are employed for drug challenge studies (approximately 50% of available pups may fail to reach this criterion). On test days each pup receives an oral dose or an s.c. or i.p. injection of test compound or vehicle and is then
25 immediately returned to the home cage with its mother and siblings for 30 to 60 minutes (or for up to 4 hours following an oral dose, dependant upon the oral pharmacokinetics of the test compound) before social isolation for 15 minutes as described above. The duration of vocalisation on drug treatment days is expressed as a percentage of the pre-treatment baseline
30 value for each animal. The same subjects are retested once weekly for up

to 6 weeks. Between 6 and 8 animals receive each test compound at each dose tested.

As used herein, the term "CNS-penetrant" refers to NK-1 receptor antagonists which are able to inhibit NK-1 receptor antagonist-induced
5 foot-tapping in the gerbil as hereinafter defined.

Essentially, hind foot-tapping in the gerbil induced by infusion of the NK-1 receptor agonist, GR73632 (d Ala[L-Pro⁹,Me-Leu¹⁰]-substance P-(7-11)), under anaesthesia, directly into the central ventricles is inhibited when a CNS-penetrant NK-1 receptor antagonist is administered
10 intravenously immediately prior to GR73632 challenge, wherein hind foot-tapping over a period of five minutes following recovery from the anaesthesia is inhibited with an $ID_{50} \leq 3\text{mg/kg}$, and preferably with an $ID_{50} \leq 1\text{mg/kg}$.

In an alternative method, the NK-1 receptor antagonist is
15 administered orally, 1 hour prior to GR73632 challenge, wherein the foot-tapping over a period of five minutes following recovery from anaesthesia is inhibited with an $ID_{50} \leq 30\text{mg/kg}$, and preferably with an $ID_{50} \leq 10\text{mg/kg}$.

CNS-penetrant NK-1 receptor antagonists of use in the present invention are also effective in the attenuation of separation-induced
20 vocalisations by guinea-pig pups as hereinafter defined.

Essentially, a vocalisation response in guinea-pig pups is induced by isolation from their mothers and littermates, which response is attenuated when a CNS-penetrant NK-1 receptor antagonist is administered subcutaneously 30 minutes prior to isolation, wherein
25 vocalisations during the first 15 minutes of isolation are attenuated with an $ID_{50} \leq 20\text{mg/kg}$, preferably with an $ID_{50} \leq 10\text{mg/kg}$, and especially with an $ID_{50} \leq 5\text{mg/kg}$.

In an alternative method, the NK-1 receptor antagonist is administered orally, 4 hours prior to isolation, wherein vocalisations
30 during the first 15 minutes of isolation are attenuated with an

$ID_{50} \leq 20 \text{ mg/kg}$, preferably with an $ID_{50} \leq 10 \text{ mg/kg}$, and especially with an $ID_{50} \leq 5 \text{ mg/kg}$.

A suitable selection cascade for NK_1 antagonists of use according to the present invention is as follows:

- 5 (i) Determine affinity for human NK_1 receptor in radioligand binding studies (Assay 1); select compounds with $IC_{50} \leq 10 \text{ nM}$, preferably $IC_{50} \leq 2 \text{ nM}$, especially $IC_{50} \leq 1 \text{ nM}$.

- (ii) Determine ability of compounds to penetrate CNS by their ability to inhibit foot tapping in gerbils induced by central injection of an NK_1 agonist (Assay 2); select compounds that inhibit foot tapping with $ID_{50} \leq 3 \text{ mg/kg i.v.}$, and preferably $ID_{50} \leq 1 \text{ mg/kg i.v.}$ when administered immediately prior to central NK_1 agonist challenge, or $ID_{50} \leq 30 \text{ mg/kg p.o.}$, and preferably $ID_{50} \leq 10 \text{ mg/kg p.o.}$ 1 hour prior to challenge.

- (iii) Determine central duration of action of compounds in gerbil foot tapping assay following intravenous administration 24 hours prior to central NK_1 agonist challenge; select compounds showing ≤ 25 -fold loss of potency compared with ID_{50} determined in step (ii) above with the proviso that $ID_{50} \leq 10 \text{ mg/kg i.v.}$, and preferably $\leq 5 \text{ mg/kg i.v.}$ after 24 hour pre-treatment.

- 20 (iv) Determine oral bioavailability of compounds by pharmacokinetic analysis, activity in gerbil foot tapping assay following oral administration and/or by ability to inhibit cisplatin-induced emesis in ferrets (Assay 3); select compounds with $ID_{90} \leq 3 \text{ mg/kg p.o.}$, and preferably $ID_{90} \leq 1 \text{ mg/kg p.o.}$

- 25 Particularly preferred compounds of use in the present invention are identified using steps (i) to (iv) followed by step (v):

- (v) Determine activity of compounds in assays sensitive to conventional antidepressant/anxiolytic drugs (inhibition of pharmacologically evoked foot tapping in gerbils and/or inhibition of distress vocalisations in guinea-pig pups (Assay 4)). Select compounds with $ID_{50} \leq 20 \text{ mg/kg}$, and preferably $ID_{50} \leq 10 \text{ mg/kg}$.

Yet further preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK-1 receptor binding criteria of step (i) which, in addition, have ≤ 5 -fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.

The NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, the preparation of which is described in International Patent Specification No.

WO 95/18124 and US Patent No. 5,612,337. In the aforementioned assays, this compound has the following activity:

human NK-1 receptor binding:	IC ₅₀ = 0.12 nM
gerbil foot-tapping (5 mins.):	ID ₅₀ = 0.38 mg/kg i.v.
gerbil foot-tapping (24 hrs.):	ID ₅₀ = 2.2 mg/kg i.v.
ferret emesis:	ID ₉₀ = 1 mg/kg p.o.
guinea-pig vocalisation (4 hr. pre-treatment):	ID ₅₀ = 0.91 mg/kg p.o.

The following example illustrates pharmaceutical compositions according to the invention.

EXAMPLE 1 Tablets containing 50-300mg of NK-1 antagonist

	<u>Amount mg</u>		
NK-1 antagonist	50.0	100.0	300.0
Microcrystalline cellulose	80.0	80.0	80.0
Modified food corn starch	80.0	80.0	80.0
Lactose	189.5	139.5	139.5
Magnesium Stearate	0.5	0.5	0.5

The active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is
5 then compressed into tablets containing 50mg, 100mg and 300mg of the NK-1 receptor antagonist per tablet.

CLAIMS

1. Use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders.
2. Use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants, SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants, SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated.
3. Use of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated.
4. An oral pharmaceutical composition for the treatment of cognitive disorders which comprises 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-

(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.

5. A method for the treatment or prevention of cognitive disorders, which method comprises the oral administration to a patient in need of such treatment of an effective amount of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

10

6. A method for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants, SSRIs, serotonin agents or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants, SSRIs, serotonin agents or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

15
20

7. A method for the treatment or prevention of cognitive disorders in a patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine, or a pharmaceutically acceptable salt thereof.

25
30

8. A use according to claim 1, 2 or 3, or a composition according to claim 4 or a method according to claim 5, 6 or 7 wherein the cognitive disorders are selected from dementia, amnesic disorders and cognitive disorders not otherwise specified.

5

9. A use, composition or method according to claim 10 wherein the dementia is caused by degenerative disorders; lesions, trauma, infections, vascular disorders, toxins, anoxia, vitamin deficiency or endocrine disorders.

10

10. A use, composition or method according to claim 8 wherein the amnesic disorders are caused by: alcohol and other causes of thiamine deficiency; bilateral temporal lobe damage due to herpes simplex encephalitis and other limbic encephalitis, neuronal loss secondary to anoxia/hypoglycaemia/severe convulsions, and surgery; degenerative disorders; vascular disorders; or pathology around ventricle III.

15

11. A use according to claim 1, 2 or 3, or a composition according to claim 4 or a method according to claim 5, 6 or 7 wherein the cognitive disorders are due to cognitive impairment resulting from other medical conditions.

20

INTERNATIONAL SEARCH REPORT

 National Application No
 PCT/GB 01818

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and where practical search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No
X	WO 95 18124 A (MERCK SHARP & DOHME ;BAKER RAYMOND (GB); HARRISON TIMOTHY (GB); MA) 6 July 1995 (1995-07-06) cited in the application page 23, line 6-8 page 30, line 26 - line 28 page 101; example 89 ---	1-11
P, X	WO 99 07375 A (MERCK SHARP & DOHME ;RUPNIAK NADIA MELANIE (GB)) 18 February 1999 (1999-02-18) claims ---	1-11
Y	WO 96 29326 A (GLAXO GROUP LTD ;GIBLIN GERARD MARTIN PAUL (GB); SHARRATT PETER JO) 26 September 1996 (1996-09-26) page 7, line 4 - line 9 ---	1-11
	--- -/--	

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 July 1999

Date of mailing of the international search report

04/08/1999

Name and mailing address of the ISA

 European Patent Office P B 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040 Tx 31 651 epo nl.
 Fax (+31-70) 340-3016

Authorized officer

Seegert, K

INTERNATIONAL SEARCH REPORT

 International Application No.
 PCT/GB 99/01818

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	WO 96 24353 A (LILLY CO ELI ; JOHNSON KIRK W (US); PHEBUS LEE A (US)) 15 August 1996 (1996-08-15) page 5, line 18 - line 24 ---	1-11
Y	US 5 719 147 A (LADDUWAHETTY TAMARA ET AL) 17 February 1998 (1998-02-17) column 48, line 18 - line 26 ---	1-11
Y	WO 98 13369 A (HAWORTH KAREN ELIZABETH ; MERCK SHARP & DOHME (GB); SEWARD EILEEN M) 2 April 1998 (1998-04-02) page 18, line 2 - line 26 ---	1-11
Y	WO 96 29328 A (MERCK SHARP & DOHME ; HAWORTH KAREN ELIZABETH (GB); OWEN SIMON NEIL) 26 September 1996 (1996-09-26) page 15, line 27 - page 16, line 20 ---	1-11
Y	WO 97 49710 A (ELLIOTT JASON MATTHEW ; HOLLINGWORTH GREGORY JOHN (GB); KULAGOWSKI) 31 December 1997 (1997-12-31) page 15, line 8 - line 30 ---	1-11
Y	EP 0 533 280 A (GLAXO GROUP LTD) 24 March 1993 (1993-03-24) page 17, line 31 - line 37 ---	1-11
P, Y	WO 99 25714 A (PFIZER PHARMA ; SATAKE KUNIO (JP); PFIZER (US)) 27 May 1999 (1999-05-27) page 4, line 16 ---	1-11
P, Y	WO 98 54187 A (KULAGOWSKI JANUSZ JOZEF ; MERCK SHARP & DOHME (GB); RAUBO PIOTR ALP) 3 December 1998 (1998-12-03) page 16, line 33 - page 17, line 21 -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. International Application No

PCT/GB 96/01818

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9518124 A	06-07-1995	AU 685209 B	15-01-1998
		AU 1322395 A	17-07-1995
		BG 100644 A	31-03-1997
		BR 9408442 A	05-08-1997
		CA 2178219 A	06-07-1995
		CN 1139927 A	08-01-1997
		CZ 9601898 A	11-12-1996
		EP 0737192 A	16-10-1996
		HU 75872 A	28-05-1997
		JP 9507484 T	29-07-1997
		LV 11687 A	20-02-1997
		LV 11687 B	20-10-1997
		NO 962749 A	28-08-1996
		NZ 277839 A	26-01-1998
		PL 315182 A	14-10-1996
		SG 52217 A	28-09-1998
		SK 83996 A	06-11-1996
		US 5612337 A	18-03-1997
		ZA 9410317 A	10-10-1995
		FI 951762 A	13-10-1995
		HR 950222 A	31-08-1997
WO 9907375 A	18-02-1999	AU 5752998 A	01-03-1999
		AU 9160598 A	01-03-1999
		WO 9907374 A	18-02-1999
WO 9629326 A	26-09-1996	AU 5333596 A	08-10-1996
		EP 0815104 A	07-01-1998
		JP 11502810 T	09-03-1999
		ZA 9602200 A	30-10-1996
WO 9624353 A	15-08-1996	AU 4918796 A	27-08-1996
US 5719147 A	17-02-1998	US 5872116 A	16-02-1999
		AU 701862 B	04-02-1999
		AU 1437595 A	03-07-1995
		BG 100715 A	31-01-1997
		BR 9408351 A	26-08-1997
		CA 2178949 A	22-06-1995
		CN 1142819 A	12-02-1997
		CZ 9601772 A	11-12-1996
		EP 0734381 A	02-10-1996
		FI 962489 A	13-08-1996
		HR 941000 A	30-06-1997
		HU 76476 A	29-09-1997
		JP 9506628 T	30-06-1997
		LV 11617 A	20-12-1996
		LV 11617 B	20-04-1997
		NO 962523 A	16-08-1996
		NZ 278222 A	27-05-1998
		PL 315153 A	14-10-1996
		SK 75396 A	04-12-1996
		WO 9516679 A	22-06-1995
		US 5637699 A	10-06-1997
		ZA 9410008 A	15-07-1996
		AU 4156893 A	06-01-1994
		AU 4656193 A	24-01-1994
		BG 99274 A	30-04-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 95/0818

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5719147 A		CA 2099233 A	30-12-1993
		CN 1087902 A	15-06-1994
		CZ 9403330 A	13-09-1995
		EP 0577394 A	05-01-1994
		FI 946133 A	28-12-1994
		HR 931003 A	28-02-1995
		HU 71809 A	28-02-1996
		IL 106142 A	18-03-1997
		JP 2634372 B	23-07-1997
		JP 6172178 A	21-06-1994
		MX 9303888 A	31-03-1994
		NO 945064 A	28-02-1995
		NZ 254476 A	25-09-1996
		PL 174506 B	31-08-1998
		SI 9300346 A	31-12-1993
		SK 160094 A	11-07-1995
		WO 9400440 A	06-01-1994
		AU 4160893 A	06-01-1994
		ZA 9304624 A	20-06-1994
WO 9813369 A	02-04-1998	AU 4310097 A	17-04-1998
		EP 0929554 A	21-07-1999
WO 9629328 A	26-09-1996	AU 5009896 A	08-10-1996
		CA 2215699 A	26-09-1996
		EP 0815107 A	07-01-1998
		JP 11502221 T	23-02-1999
		US 5877316 A	02-03-1999
WO 9749710 A	31-12-1997	AU 3102097 A	14-01-1998
		EP 0906315 A	07-04-1999
		NO 985977 A	22-02-1999
		PL 330235 A	10-05-1999
		AU 5485898 A	29-06-1998
		AU 5558998 A	29-06-1998
		AU 5559098 A	29-06-1998
		AU 5559198 A	29-06-1998
		AU 5559298 A	29-06-1998
		AU 5559398 A	29-06-1998
		AU 5559498 A	29-06-1998
		AU 5561398 A	29-06-1998
		AU 5752798 A	29-06-1998
		AU 5753098 A	29-06-1998
		WO 9824438 A	11-06-1998
		WO 9824439 A	11-06-1998
		WO 9824440 A	11-06-1998
		WO 9824441 A	11-06-1998
		WO 9824442 A	11-06-1998
		WO 9824443 A	11-06-1998
		WO 9824444 A	11-06-1998
		WO 9824445 A	11-06-1998
		WO 9824446 A	11-06-1998
		WO 9824447 A	11-06-1998
		HR 970648 A	31-08-1998
EP 0533280 A	24-03-1993	AU 657996 B	30-03-1995
		AU 2458392 A	25-03-1993
		CA 2078578 A	21-03-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/GB 98/01818

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0533280 A		EP 0916346 A	19-05-1999
		EP 0919245 A	02-06-1999
		IL 103214 A	12-03-1999
		JP 6107563 A	19-04-1994
		US 5538982 A	23-07-1996
		US 5798363 A	25-08-1998
		US 5360820 A	01-11-1994
		ZA 9207156 A	18-03-1994
WO 9925714 A	27-05-1999	NONE	
WO 9854187 A	03-12-1998	AU 7665398 A	30-12-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.